Richard Stanley Bedlack
Professor of Neurology
Overview
2. Epidemiologic studies to better understand the causes and variability in prognosis of amyotrophic lateral sclerosis and diabetic neuropathy.
3. Basic science studies to develop novel biomarkers for amyotrophic lateral sclerosis.
Selected Grants
A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MN-166 (IBUDILAST) FOLLOWED BY AN OPEN-LABEL EXTENSION IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS awarded by MediciNova, INC. (Principal Investigator). 2020 to 2022
EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS: OPEN-LABEL EXTENSION FOR PATIENTS COMPLETING STUDY 3119002 awarded by Orion Corporation (Principal Investigator). 2019 to 2021
ALS Telemedicine awarded by Amyotrophic Lateral Sclerosis Association (Principal Investigator). 2020 to 2021
The Duke ALS Association Certified Center awarded by Amyotrophic Lateral Sclerosis Association (Principal Investigator). 2018 to 2021
Identification of diagnostic peptides for the detection of sporadic amyotrophic lateral sclerosis (sALS) awarded by Affinergy, LLC (Principal Investigator). 2020
Clinical Research in ALS & Related Disorders for Therapeutic Development (CREATE) awarded by University of Miami (Principal Investigator). 2019 to 2020
A Pilot Trial of Triheptanoin for People with Amyotrophic Lateral Sclerosis (PALS) awarded by Ultragenyx Pharmaceutical (Principal Investigator). 2018 to 2020
Duke ALS Telemedicine Clinic awarded by Amyotrophic Lateral Sclerosis Association (Principal Investigator). 2018 to 2020
Integrated Genomics in Clinical ALS (GTAC) awarded by Columbia University (Principal Investigator). 2016 to 2019
Protocol CY 5022: A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK-2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) awarded by Cytokinetics, Inc. (Principal Investigator). 2017 to 2019
Pages
Brizzi, Kate T., et al. “Understanding the needs of people with ALS: a national survey of patients and caregivers.” Amyotroph Lateral Scler Frontotemporal Degener, vol. 21, no. 5–6, Aug. 2020, pp. 355–63. Pubmed, doi:10.1080/21678421.2020.1760889. Full Text
Andrews, Jinsy A., et al. “Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities.” Muscle Nerve, vol. 62, no. 2, Aug. 2020, pp. 182–86. Pubmed, doi:10.1002/mus.26989. Full Text
Crayle, Jesse, et al. “Total serum immunoglobulin A in ALS.” Amyotroph Lateral Scler Frontotemporal Degener, July 2020, pp. 1–5. Pubmed, doi:10.1080/21678421.2020.1790608. Full Text
Bedlack, Richard, et al. “ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors.” Amyotroph Lateral Scler Frontotemporal Degener, vol. 21, no. 3–4, May 2020, pp. 216–21. Pubmed, doi:10.1080/21678421.2019.1690519. Full Text
Mitsumoto, Hiroshi, et al. “Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis.” Amyotroph Lateral Scler Frontotemporal Degener, vol. 21, no. 3–4, May 2020, pp. 263–72. Pubmed, doi:10.1080/21678421.2020.1746810. Full Text
Fournier, Christina N., et al. “Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).” Jama Neurol, vol. 77, no. 4, Apr. 2020, pp. 480–88. Pubmed, doi:10.1001/jamaneurol.2019.4490. Full Text
Pytte, Julia, et al. “Association of a structural variant within the SQSTM1 gene with amyotrophic lateral sclerosis.” Neurol Genet, vol. 6, no. 2, Apr. 2020, p. e406. Pubmed, doi:10.1212/NXG.0000000000000406. Full Text
Berry, J. D., et al. “Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study.” Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Jan. 2020. Scopus, doi:10.1080/21678421.2020.1804939. Full Text
Urbi, Berzenn, et al. “Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.” Bmj Open, vol. 9, no. 11, Nov. 2019, p. e029449. Pubmed, doi:10.1136/bmjopen-2019-029449. Full Text
Bedlack, Rick. “ALSUntangled 48: Perampanel (Fycompa).” Amyotroph Lateral Scler Frontotemporal Degener, vol. 20, no. 5–6, Aug. 2019, pp. 453–56. Pubmed, doi:10.1080/21678421.2019.1573850. Full Text
Pages
Bedlack, Richard S., et al. “Scrutinizing enrollment in ALS clinical trials: Room for improvement?” Neurology, vol. 70, no. 11, LIPPINCOTT WILLIAMS & WILKINS, 2008, pp. A344–A344.
Bedlack, R. S., and S. Torres. “Multifocal motor neuropathy with upper motor neuron signs.” Muscle & Nerve, vol. 34, no. 4, JOHN WILEY & SONS INC, 2006, pp. 514–514.
Bedlack, R. S., et al. “Apolipoprotein E genotype is a risk factor for diabetic neuropathy.” Annals of Neurology, vol. 52, no. 6, WILEY-LISS, 2002, pp. 866–866.
Gross, E., et al. “Fluorescent imaging of membrane potential components.” Analytical Use of Fluorescent Probes in Oncology, edited by E. Kohen and J. G. Hirschberg, vol. 286, PLENUM PRESS DIV PLENUM PUBLISHING CORP, 1996, pp. 249–56.
BEDLACK, R. S., et al. “ENDOGENOUS ELECTRIC-FIELDS WITHIN THE NEURONAL PLASMALEMMA - NONUNIFORMITIES SUGGESTING DIFFERENTIAL VOLTAGE-DEPENDENCE.” Biophysical Journal, vol. 66, no. 2, BIOPHYSICAL SOCIETY, 1994, pp. A387–A387.
GROSS, E., et al. “DUAL-WAVELENGTH RATIOMETRIC FLUORESCENCE MEASUREMENT OF THE MEMBRANE DIPOLE POTENTIAL.” Biophysical Journal, vol. 66, no. 2, BIOPHYSICAL SOCIETY, 1994, pp. A387–A387.
BEDLACK, R. S., et al. “ELECTRIC FIELD-BIASED N1E-115 GROWTH CONE FILOPODIAL PROTRUSIONS ARE INHIBITED BY VERAPAMIL.” Biophysical Journal, vol. 64, no. 2, BIOPHYSICAL SOCIETY, 1993, pp. A101–A101.